Ivabradine in the treatment of systolic heart failure - A systematic review and meta-analysis
Open Access
- 1 January 2017
- journal article
- review article
- Published by Baishideng Publishing Group Inc. in World Journal of Cardiology
- Vol. 9 (2) , 182-190
Abstract
To perform a systematic-review and meta-analysis to compare outcomes of ivabradine combined with beta-blocker to beta-blocker alone in heart failure with reduced ejection fraction (HFrEF). We searched PubMed, Cochrane, EMBASE, CINAHL and Web of Science for trials comparing ivabradine + beta-blocker to beta-blocker alone in HFrEF. We performed a systematic-review and meta-analysis of published literature. Primary end-point was combined end point of cardiac death and hospitalization for heart failure. Six studies with 17671 patients were included. Mean follow-up was 8.7 ± 7.9 mo. Combined end-point of heart failure readmission and cardiovascular death was better in ivabradine + beta-blocker group compared to beta-blocker alone (RR: 0.93, 95%CI: 0.79-1.09, P = 0.354). Mean difference (MD) in heart rate was higher in the ivabradine + beta-blocker group (MD: 6.14, 95%CI: 3.80-8.48, P < 0.001). There was no difference in all cause mortality (RR: 0.98, 95%CI: 0.89-1.07, P = 0.609), cardiovascular mortality (RR: 0.99, 95%CI: 0.86-1.15, P = 0.908) or heart failure hospitalization (RR: 0.87, 95%CI: 0.68-1.11, P = 0.271). From the available clinical trials, ivabradine + beta-blocker resulted in a significantly greater reduction in HR coupled with improvement in combined end-point of heart failure readmission and cardiovascular death but with no improvement in all cause or cardiovascular mortality. Given the limited evidence, further randomized controlled trials are essential before widespread clinical application of ivabradine + beta-blocker is advocated for HFrEF.Keywords
This publication has 27 references indexed in Scilit:
- ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012European Journal of Heart Failure, 2012
- Efficacy of Ivabradine in Combination with Beta-Blocker Versus Uptitration of Beta-Blocker in Patients with Stable AnginaCardiovascular Drugs and Therapy, 2011
- Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trialThe Lancet, 2010
- Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled studyThe Lancet, 2010
- Coma With Absent Brainstem Reflexes Resulting From Zolpidem OverdoseAmerican Journal of Therapeutics, 2010
- If Inhibition with IvabradineDrug Safety, 2008
- Resting Heart Rate in Cardiovascular DiseaseJACC, 2007
- The Funny CurrentDrugs, 2007
- Characterization of the Hyperpolarization-Activated Current, I f , in Ventricular Myocytes From Human Failing HeartCirculation, 1997
- Control of myocardial oxygen consumptionThe American Journal of Cardiology, 1971